Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
07:00am, Wednesday, 11'th Jun 2025
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
2 Soaring Stocks Wth More Upside Potential
03:19am, Thursday, 05'th Jun 2025
Although fundamental investing wisdom tells us to "buy low," it may still be worthwhile to purchase shares of top companies following significant runs. Any point can be considered low -- even after ma
Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?
12:37pm, Wednesday, 04'th Jun 2025
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Axsome Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Thursday, 29'th May 2025
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ann
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
07:00am, Tuesday, 27'th May 2025
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders,
3 High-Flying Stocks That Could Soar Even More
06:40am, Saturday, 24'th May 2025
Many investors love the "big mo." That's short for "big momentum.
Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis
07:30pm, Wednesday, 14'th May 2025
Explore the exciting world of Axsome Therapeutics (AXSM -1.70%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
07:00am, Tuesday, 13'th May 2025
Previous term loan facility retired NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervo
Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years
07:08am, Monday, 12'th May 2025
Regardless of how stocks are performing right now, history tells us that the market tends to generate solid returns over long periods. Investors can do even better than the average market performance
3 Monster Stocks in the Making
11:15am, Sunday, 11'th May 2025
Think of some of the biggest and most successful stocks on the market. Now, go back 20 or 30 years.
Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns
12:48pm, Tuesday, 06'th May 2025
Axsome Therapeutics reported strong Q1 2025 earnings, with revenue and EPS beats driven by Auvelity and Sunosi, despite high SG&A expenses and net loss. Auvelity shows promising growth in the competit
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
10:41am, Tuesday, 06'th May 2025
Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.
Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript
11:44am, Monday, 05'th May 2025
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Piz
Axsome Therapeutics Clocks Around 60% Topline Growth In Q1
10:41am, Monday, 05'th May 2025
Axsome Therapeutics Inc AXSM on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating the consensus of $119.87 million.
Axsome (AXSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
10:35am, Monday, 05'th May 2025
While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to
